Short Interest in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Rises By 35.8%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 41,351 shares, an increase of 35.8% from the January 29th total of 30,452 shares. Currently, 6.7% of the shares of the company are short sold. Based on an average daily volume of 25,502 shares, the short-interest ratio is presently 1.6 days. Based on an average daily volume of 25,502 shares, the short-interest ratio is presently 1.6 days. Currently, 6.7% of the shares of the company are short sold.

Institutional Investors Weigh In On CNS Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Armistice Capital LLC bought a new position in CNS Pharmaceuticals in the 2nd quarter valued at about $335,000. Boothbay Fund Management LLC acquired a new stake in shares of CNS Pharmaceuticals during the 4th quarter worth approximately $71,000. Finally, Ikarian Capital LLC acquired a new stake in shares of CNS Pharmaceuticals during the 4th quarter worth approximately $241,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

CNS Pharmaceuticals Price Performance

NASDAQ:CNSP traded up $0.02 during trading hours on Monday, reaching $3.13. 2,996 shares of the company were exchanged, compared to its average volume of 46,439. The business has a 50 day moving average of $5.14 and a 200 day moving average of $6.66. CNS Pharmaceuticals has a 1-year low of $2.94 and a 1-year high of $55.20. The company has a market capitalization of $1.94 million, a P/E ratio of -0.10 and a beta of 2.70.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CNS Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $20.00.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.